Expression of tumor-associated calcium signal transducer 2 in patients with salivary adenoid cystic carcinoma: 
Correlation with clinicopathological features and prognosis

Xia,Yichao; Li,Bo; Gao,Ning; Xia,Hui; Men,Yi; Liu,Ying; Liu,Zhe; Chen,Qianming; Li,Longjiang

doi:10.3892/ol.2014.2400

Expression of tumor-associated calcium signal transducer 2 in patients with salivary adenoid cystic carcinoma: Correlation with clinicopathological features and prognosis

Authors:
- Yichao Xia
- Bo Li
- Ning Gao
- Hui Xia
- Yi Men
- Ying Liu
- Zhe Liu
- Qianming Chen
- Longjiang Li
View Affiliations

Affiliations: Department of Head and Neck Oncology Surgery, West China College of Stomatology, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Pathology, State Key Laboratory of Oral Diseases, West China College of Stomatology, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: July 31, 2014 https://doi.org/10.3892/ol.2014.2400
Pages: 1670-1674

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Salivary adenoid cystic carcinoma (SACC) is a common salivary malignancy. The current treatment option for SACC is complete surgical excision with postoperative radiotherapy. The prognosis remains unsatisfactory, due to frequent local recurrence and distant metastases that directly reduce the overall survival time. Previous studies have shown that overexpression of tumor‑associated calcium signal transducer 2 (TACSTD2) is associated with poor prognosis in various human epithelial cancers. The expression of TACSTD2 in SACC is currently unknown. The present study therefore aimed to retrospectively investigate TACSTD2 protein expression by immunohistochemistry on paraffin‑embedded primary tumor tissue samples from a series of consecutive SACC patients (n=81). The correlation of TACSTD2 expression with clinicopathological variables was evaluated using either the Kruskal‑Wallis or Mann‑Whitney statistical tests. The survival curves were plotted using the Kaplan‑Meier method. The parameters of prognostic significance found by univariate analysis were verified in a multivariate Cox regression model. Overexpression of TACSTD2 was detected in 35/81 (44%) SACC patients and was significantly associated with a decreased overall survival (P<0.01). Univariate analysis showed that TACSTD2 overexpression was correlated with TNM stage (P=0.020), local recurrence (P=0.002) and distant metastasis (P=0.001). Multivariate analyses further revealed that TACSTD2 may be an independent prognostic indicator. In conclusion, TACTSD2 could be recognized as an independent prognostic indicator for SACC. Gene therapy targeting TACSTD2 may be a possible treatment approach for patients with SACC overexpressing this cell‑surface marker.

View Figures

View References

1	Li LJ, Li Y, Wen YM, et al: Clinical analysis of salivary gland tumor cases in West China in past 50 years. Oral Oncol. 44:187–192. 2008.
2	Spiro RH: Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg. 8:177–184. 1986.
3	Gao M, Hao Y, Huang MX, et al: Clinicopathological study of distant metastases of salivary adenoid cystic carcinoma. Int J Oral Maxillofac Surg. 42:923–928. 2013.
4	Trzpis M, McLaughlin PM, de Leij LM and Harmsen MC: Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol. 171:386–395. 2007.
5	Ripani E, Sacchetti A, Corda D and Alberti S: Human Trop-2 is a tumor-associated calcium signal transducer. Int J Cancer. 76:671–676. 1998.
6	Lipinski M, Parks DR, Rouse RV and Herzenberg LA: Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc Natl Acad Sci USA. 78:5147–5150. 1981.
7	Linnenbach AJ, Wojcierowski J, Wu SA, et al: Sequence investigation of the major gastrointestinal tumor-associated antigen gene family, GA733. Proc Natl Acad Sci USA. 86:27–31. 1989.
8	Guerra E, Trerotola M, Aloisi AL, et al: The Trop-2 signalling network in cancer growth. Oncogene. 32:1594–1600. 2013.
9	El Sewedy T, Fornaro M and Alberti S: Cloning of the murine TROP2 gene: conservation of a PIP2-binding sequence in the cytoplasmic domain of TROP-2. Int J Cancer. 75:324–330. 1998.
10	Wang J, Day R, Dong Y, et al: Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther. 7:280–285. 2008.
11	Fong D, Spizzo G, Gostner JM, et al: TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol. 21:186–191. 2008.
12	Fong D, Moser P, Krammel C, et al: High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer. 99:1290–1295. 2008.
13	Liu T, Liu Y, Bao X, et al: Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway. PloS One. 8:e758642013.
14	Ning S, Guo S, Xie J, Xu Y, Lu X and Chen Y: TROP2 correlates with microvessel density and poor prognosis in hilar cholangiocarcinoma. J Gastrointest Surg. 17:360–368. 2013.
15	Mühlmann G, Spizzo G, Gostner J, et al: TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol. 62:152–158. 2009.
16	Bignotti E, Todeschini P, Calza S, et al: Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer. 46:944–953. 2010.
17	da Cruz Perez DE, de Abreu Alves F, Nobuko Nishimoto I, et al: Prognostic factors in head and neck adenoid cystic carcinoma. Oral Oncol. 42:139–146. 2006.
18	Seifert G and Sobin LH: The World Health Organization’s Histological Classification of Salivary Gland Tumors. A commentary on the second edition. Cancer. 70:379–385. 1992.
19	Linnenbach AJ, Seng BA, Wu S, et al: Retroposition in a family of carcinoma-associated antigen genes. Mol Cell Biol. 13:1507–1515. 1993.
20	Nakashima K, Shimada H, Ochiai T, et al: Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int J Cancer. 112:1029–1035. 2004.
21	Guerra E, Trerotola M, Dell’ Arciprete R, et al: A bicistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer. Cancer Res. 68:8113–8121. 2008.
22	Cubas R, Zhang S, Li M, Chen C and Yao Q: Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer. 9:2532010.
23	Biliran H Jr, Wang Y, Banerjee S, et al: Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res. 11:6075–6086. 2005.
24	Trerotola M, Li J, Alberti S and Languino LR: Trop-2 inhibits prostate cancer cell adhesion to fibronectin through the β1 integrin-RACK1 axis. J Cell Physiol. 227:3670–3677. 2012.
25	Trerotola M, Jernigan DL, Liu Q, et al: Trop-2 promotes prostate cancer metastasis by modulating β(1) integrin functions. Cancer Res. 73:3155–3167. 2013.
26	de Bono JS, Tolcher AW, Forero A, et al: ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas. Clin Cancer Res. 10:7555–7565. 2004.
27	Mosolits S, Markovic K, Frodin JE, et al: Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients. Clin Cancer Res. 10:5391–5402. 2004.
28	Bignotti E, Ravaggi A, Romani C, et al: Trop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: implications for immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody. Int J Gynecol Cancer. 21:1613–1621. 2011.
29	Raji R, Guzzo F, Carrara L, et al: Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. J Exp Clin Cancer Res. 30:1062011.
30	Varughese J, Cocco E, Bellone S, et al: Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody. Cancer. 117:3163–3172. 2011.
31	Govindan SV, Stein R, Qu Z, et al: Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel. Breast Cancer Res Treat. 84:173–182. 2004.
32	Lin H, Zhang H, Wang J, et al: A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo. Int J Cancer. 34:1239–1249. 2014.